Cargando…
Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
BACKGROUND: Small intestinal Neuroendocrine Neoplasms (SI‐NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI‐NEN in Auckland, Aotearoa New Zealand (AoNZ). METHODS: A retrospective study of all patients diagnosed wit...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541869/ https://www.ncbi.nlm.nih.gov/pubmed/35762209 http://dx.doi.org/10.1111/ans.17851 |
_version_ | 1784804021132853248 |
---|---|
author | McGuinness, Matthew J. Woodhouse, Braden Harmston, Christopher Parker, Kate Kramer, Nicole Findlay, Michael Print, Cristin Merrie, Arend Lawrence, Ben |
author_facet | McGuinness, Matthew J. Woodhouse, Braden Harmston, Christopher Parker, Kate Kramer, Nicole Findlay, Michael Print, Cristin Merrie, Arend Lawrence, Ben |
author_sort | McGuinness, Matthew J. |
collection | PubMed |
description | BACKGROUND: Small intestinal Neuroendocrine Neoplasms (SI‐NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI‐NEN in Auckland, Aotearoa New Zealand (AoNZ). METHODS: A retrospective study of all patients diagnosed with a jejunal or ileal SI‐NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data. RESULTS: One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10‐year disease‐specific survival for all patients was 66.1% (95% CI 56.5–75.7%) and 61.8% (95% CI 51.8–71.8%), respectively. Ten‐year disease‐specific survival was 100% for stage I and II, 74% (95%CI 61.7–84.4%) for stage III and 33.9% (95%CI 16.9–35.6%) for stage IV SI‐NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92–5.5) nor distant resection (HR 1.72, 95% CI 0.63–4.7) were significantly associated with a disease‐specific or overall survival benefit. CONCLUSION: This study demonstrates that stage at SI‐NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection. |
format | Online Article Text |
id | pubmed-9541869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-95418692022-10-14 Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand McGuinness, Matthew J. Woodhouse, Braden Harmston, Christopher Parker, Kate Kramer, Nicole Findlay, Michael Print, Cristin Merrie, Arend Lawrence, Ben ANZ J Surg General Surgery BACKGROUND: Small intestinal Neuroendocrine Neoplasms (SI‐NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI‐NEN in Auckland, Aotearoa New Zealand (AoNZ). METHODS: A retrospective study of all patients diagnosed with a jejunal or ileal SI‐NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data. RESULTS: One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10‐year disease‐specific survival for all patients was 66.1% (95% CI 56.5–75.7%) and 61.8% (95% CI 51.8–71.8%), respectively. Ten‐year disease‐specific survival was 100% for stage I and II, 74% (95%CI 61.7–84.4%) for stage III and 33.9% (95%CI 16.9–35.6%) for stage IV SI‐NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92–5.5) nor distant resection (HR 1.72, 95% CI 0.63–4.7) were significantly associated with a disease‐specific or overall survival benefit. CONCLUSION: This study demonstrates that stage at SI‐NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection. John Wiley & Sons Australia, Ltd 2022-06-28 2022 /pmc/articles/PMC9541869/ /pubmed/35762209 http://dx.doi.org/10.1111/ans.17851 Text en © 2022 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | General Surgery McGuinness, Matthew J. Woodhouse, Braden Harmston, Christopher Parker, Kate Kramer, Nicole Findlay, Michael Print, Cristin Merrie, Arend Lawrence, Ben Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand |
title | Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand |
title_full | Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand |
title_fullStr | Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand |
title_full_unstemmed | Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand |
title_short | Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand |
title_sort | survival of patients with small bowel neuroendocrine neoplasms in auckland, aotearoa new zealand |
topic | General Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541869/ https://www.ncbi.nlm.nih.gov/pubmed/35762209 http://dx.doi.org/10.1111/ans.17851 |
work_keys_str_mv | AT mcguinnessmatthewj survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT woodhousebraden survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT harmstonchristopher survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT parkerkate survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT kramernicole survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT findlaymichael survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT printcristin survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT merriearend survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand AT lawrenceben survivalofpatientswithsmallbowelneuroendocrineneoplasmsinaucklandaotearoanewzealand |